(Q37803420)

23 August 2017

title

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. (English)

1 reference

23 August 2017

Rachel E Dew

1

1 reference

23 August 2017

Scott H Kollins

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

28 October 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

17

1 reference

23 August 2017

page(s)

2907-2913

1 reference

Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Three-year follow-up of syndromal antisocial behavior in adults: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Review of medication adherence in children and adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, cro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Alopecia following initiation of lisdexamfetamine in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.531009

10.1517/14656566.2010.531009

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference